Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • JJenks
    Junior Member
    • May 2012
    • 6

    MG-RAST settings, thoughts and suggestions

    Hi All,
    I'm in the process of using MG-RAST (among other methods) to determine the taxonomic origin and function of reads from a shotgun study using Illumina reads. I've carried out a few different analyses using the online workbench, and just wanted to hear the opinions of others who have used it. I'm trying to work out if it is more sensible to have a fairly lax e-value cutoff (i.e. the default) and increase the % match and alignment length, or to up the e-value.
    I'm also still slightly confused about the definition of the e-value within MG-RAST too. I'm assuming that it's the same as BLAST, i.e. taking into account sequence length, quality of alignment and database size the e-value is representative of odds of a match by chance. Can anyone confirm this?
    Sorry if this seems confused, I'm trying to get my head around all of the concepts to ensure the science is robust.

    Thanks in advance!
  • JJenks
    Junior Member
    • May 2012
    • 6

    #2
    Just a quick update, I've since found some further details on MG-RAST, and can confirm e-values are identical to the NCBI definition found here: http://tinyurl.com/cjrjdcy. I'm finding alignments of 30-35 bp and at 95%+ identity, with an e-value of 1e-10. These would appear to be fairly good matches to me, although perhaps the alignment length is a little short.

    Thanks again.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    29 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    21 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    212 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    78 views
    0 reactions
    Last Post SEQadmin2  
    Working...